Literature DB >> 28361804

Risk adjusted mortality after hip replacement surgery: a retrospective study.

Gabriele Messina1, Silvia Forni2, Daniele Rosadini3, Manuele Falcone2, Francesca Collini2, Nicola Nante1.   

Abstract

INTRODUCTION: Hip replacement (HR) operations are increasing. Short term mortality is an indicator of quality; few studies include risk adjustment models to predict HR outcomes. We evaluated in-hospital and 30-day mortality in hospitalized patients for HR and compared the performance of two risk adjustment algorithms.
MATERIALS AND METHODS: A retrospective cohort study on hospital discharge records of patients undergoing HR from 2000 to 2005 in Tuscany Region, Italy, applied All-Patient Refined Diagnosis Related Groups (APR-DRG) and Elixhauser Index (EI) risk adjustment models to predict outcomes. Logistic regression was used to analyse the performance of the two models; C statistic (C) was used to define their discriminating ability.
RESULTS: 25 850 hospital discharge records were studied. In-hospital and 30-day crude mortality were 1.3% and 3%, respectively. Female gender was a significant (p < 0.001) protective factor under both models and had the following Odds Ratios (OR): 0.64 for in-hospital and 0.51 for 30-day mortality using APR-DRG and 0.55 and 0.48, respectively, with EI. Among EI comorbidities, heart failure and liver disease were associated with in-hospital (OR 9.29 and 5.60; p < 0.001) and 30-day (OR 6.36 and 3.26; p < 0.001) mortality. Increasing age and APR-DRG risk class were predictive of all the outcomes. Discriminating ability for in-hospital and 30-day mortality was reasonable with EI (C 0.79 and 0.68) and good with APR-DRG (C 0.86 and 0.82).
CONCLUSIONS: Our study found that gender, age, EI comorbidities and APR-DRG risk of death are predictive factors of in-hospital and 30-day mortality outcomes in patients undergoing HR. At least one risk adjustment algorithm should always be implemented in patient management.

Entities:  

Mesh:

Year:  2017        PMID: 28361804     DOI: 10.4415/ANN_17_01_09

Source DB:  PubMed          Journal:  Ann Ist Super Sanita        ISSN: 0021-2571            Impact factor:   1.663


  6 in total

1.  Comparison of Measures to Predict Mortality and Length of Stay in Hospitalized Patients.

Authors:  Jianfang Liu; Elaine Larson; Amanda Hessels; Bevin Cohen; Philip Zachariah; David Caplan; Jingjing Shang
Journal:  Nurs Res       Date:  2019 May/Jun       Impact factor: 2.381

2.  Summary perioperative risk metrics within the electronic medical record predict patient-level cost variation in pancreaticoduodenectomy.

Authors:  Christopher C Stahl; Patrick B Schwartz; Glen E Leverson; James R Barrett; Taylor Aiken; Alexandra W Acher; Sean M Ronnekleiv-Kelly; Rebecca M Minter; Sharon M Weber; Daniel E Abbott
Journal:  Surgery       Date:  2020-04-26       Impact factor: 3.982

3.  Risk factors for infection, revision, death, blood transfusion and longer hospital stay 3 months and 1 year after primary total hip or knee arthroplasty.

Authors:  Chanseok Rhee; Lynn Lethbridge; Glen Richardson; Michael Dunbar
Journal:  Can J Surg       Date:  2018-06       Impact factor: 2.089

Review 4.  The Update on Instruments Used for Evaluation of Comorbidities in Total Hip Arthroplasty.

Authors:  Łukasz Pulik; Michał Podgajny; Wiktor Kaczyński; Sylwia Sarzyńska; Paweł Łęgosz
Journal:  Indian J Orthop       Date:  2021-01-26       Impact factor: 1.251

5.  Epidemiology of Surgical Site Infections Considering the NHSN Standardized Infection Ratio in Hip and Knee Arthroplasties.

Authors:  Róża Słowik; Małgorzata Kołpa; Marta Wałaszek; Anna Różańska; Barbara Jagiencarz-Starzec; Witold Zieńczuk; Łukasz Kawik; Zdzisław Wolak; Jadwiga Wójkowska-Mach
Journal:  Int J Environ Res Public Health       Date:  2020-05-02       Impact factor: 3.390

6.  How to Improve the Drafting of Health Profiles.

Authors:  Margherita Napolitani; Giovanni Guarducci; Gulnara Abinova; Gabriele Messina; Nicola Nante
Journal:  Int J Environ Res Public Health       Date:  2022-03-15       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.